This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Bosentan in Children With Pulmonary Arterial Hypertension Extension Study (FUTURE 2)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Actelion
ClinicalTrials.gov Identifier:
NCT00319020
First received: April 26, 2006
Last updated: May 16, 2017
Last verified: May 2017
April 26, 2006
May 16, 2017
August 23, 2005
October 28, 2011   (Final data collection date for primary outcome measure)
  • Change From Baseline to End of Study (EOS) in Height for Age. [ Time Frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average ]

    In order to compare the growth data with those of healthy children, growth curves are calculated from height data collected throughout the follow-up period. For each patient, height measured at each study visit was converted to a z-score and expressed in standard deviations (SD) from WHO growth standards. The Z-score was calculated according to the following formula:

    Z-score = (observed value of the study participant - median value of the reference population) / SD value of the reference population

  • Change From Baseline to End of Study (EOS) in Body Weight [ Time Frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average ]
    The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including growth as measured by changes from baseline in body weight and height.
  • Change From Baseline to End of Study (EOS) in Systolic Blood Pressure (SBP) [ Time Frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average ]
    The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in blood pressure.
  • Change From Baseline to End of Study (EOS) in Diastolic Blood Pressure (DBP) [ Time Frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average ]
    The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in blood pressure.
  • Change From Baseline to End of Study (EOS) in Pulse Rate [ Time Frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average ]
    The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in pulse rate.
  • Proportion of Patients With Treatment-emergent Liver Function Abnormalities [ Time Frame: After baseline, up to 1 calendar day after study treatment discontinuation in FUTURE 1 or FUTURE 2, i.e. 31 months in average ]

    The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including laboratory abnormalities related to liver enzymes.

    Proportion of patients with increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above 3 times upper limit of normal (ULN) is reported here.

  • Proportion of Patients With Treatment-emergent Hemoglobin Abnormalities [ Time Frame: After baseline, up to 1 calendar day after study treatment discontinuation in FUTURE 1 or FUTURE 2, i.e. 31 months in average ]

    The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including hemoglobin abnormalities.

    Proportion of patients with marked hemoglobin decreases (i.e., decrease of or above 15% of the lower normal limit (LL)) is reported here.

  • Number of Subjects With Adverse Events Leading to Premature Discontinuation of Study Treatment [ Time Frame: From the first study drug administration in FUTURE 1, for an average of 31 months ]
  • Treatment-emergent adverse events up to 24 hours after permanent discontinuation of study drug
  • Adverse events leading to premature discontinuation of study drug
  • Serious adverse events up to 28 days after permanent discontinuation of study drug
  • Changes from Baseline to Study End in vital signs, body weight, and height
  • Treatment-emergent marked laboratory abnormalities
Complete list of historical versions of study NCT00319020 on ClinicalTrials.gov Archive Site
Not Provided
Change from Baseline in FUTURE 1 to Study End or Premature study drug discontinuation in WHO functional class, quality of life questionnaire, Global Clinical Impression scale according to parents/legal guardians and physician
Not Provided
Not Provided
 
Bosentan in Children With Pulmonary Arterial Hypertension Extension Study
An Open Label, Long-term, Safety, and Tolerability Extension Study Using the Pediatric Formulation of Bosentan in the Treatment of Children With Idiopathic or Familial Pulmonary Arterial Hypertension Who Completed FUTURE 1
The main objective of the FUTURE 2 study was to assess the long-term safety and tolerability of the pediatric formulation of bosentan in children with idiopathic pulmonary arterial hypertension or familial pulmonary arterial hypertension who completed FUTURE 1 study.
Not Provided
Interventional
Phase 3
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Pulmonary Arterial Hypertension
Drug: Bosentan
32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally
Other Names:
  • Ro 47-0203
  • Tracleer
Experimental: Bosentan
Bosentan was administered at 4 mg/kg twice daily (b.i.d.) until the end of the study. It could be down-titrated to 2 mg/kg b.i.d. if not well tolerated.
Intervention: Drug: Bosentan
Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Galiè N, Ivy DD, Jaïs X, Miera O, Rosenzweig EB, Efficace M, Kusic-Pajic A, Beghetti M. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J Cardiol. 2016 Jan 1;202:52-8. doi: 10.1016/j.ijcard.2015.08.080. Epub 2015 Aug 9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
October 28, 2011
October 28, 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed informed consent by the parents or the legal representatives.
  • Patients who completed the FUTURE 1 study.
  • Patients who tolerated bosentan pediatric formulation and for whom bosentan is considered beneficial at the end of FUTURE 1.
  • Males or females >= 2 and < 12 years of age at enrollment in FUTURE 2 (this study). Females who are menstruating must have a negative pregnancy test. A reliable method of contraception must be considered, if appropriate.

Exclusion Criteria:

  • Intolerance to bosentan despite dose reductions.
  • Any clinically significant laboratory abnormality that precludes continuation of bosentan therapy.
  • Pregnancy or breast-feeding.
  • Known hypersensitivity to bosentan or any of the excipients.
  • Premature and permanent study drug discontinuation during FUTURE 1.
Sexes Eligible for Study: All
2 Years to 11 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
France,   Germany,   Italy,   Netherlands,   Switzerland,   United Kingdom,   United States
 
 
NCT00319020
AC-052-367
2005-001967-70 ( EudraCT Number )
Not Provided
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Actelion
Actelion
Not Provided
Study Director: Andjela Kusic-Pajic, MD Actelion
Actelion
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP